Source: Alex Lavoie
Stifel Nicolaus Analyst Lowers Medtronic’s Price Target
In the competitive world of medical device manufacturing, Medtronic (NYSE: MDT) has recently experienced a significant price target revision. On June 3, 2026, industry expert, Rick Wise, a seasoned analyst from Stifel Nicolaus, lowered his price target for the medical device giant. This adjustment saw the previous target of $95.00 reduced to a more conservative $80.00, despite the stock trading at $77.95.
The price target set by an analyst gives an indication of what they believe the stock’s future value will be. This new price point represents a modest 2.63% potential increase from the stock’s price at the time of the revision. Such a cautious move by an analyst may appear somewhat surprising, especially considering Medtronic’s recent financial successes.
Medtronic Reports Best Top-Line Performance In A Decade
Despite the conservative price target revision, Medtronic has been demonstrating strong financial performance recently. In fact, the company reported its best top-line performance in a decade for the fourth quarter of 2026. This saw the company announce a significantly robust quarterly revenue of $9.81 billion, representing a 9.90% increase. Furthermore, the full-year revenue reached a commendable $36.40 billion, marking an 8.40% increase. This strong financial performance led to a stock price increase of 5.46% following the announcement.
Medtronic’s impressive growth was significantly driven by the Cardiac Ablation Solutions business. The business segment’s revenue experienced a global surge of 78% and an even more impressive 124% in the United States. This remarkable growth resulted in Medtronic gaining an additional 8 points of market share in the U.S. and put the segment on track to achieve $2.00 billion in trailing revenue.
Medtronic’s Outlook For Fiscal Year 2027
Despite the encouraging results, Medtronic’s management has given a somewhat cautious forecast for the fiscal year 2027. They anticipate organic revenue growth between 6.75% and 7.25%. However, the full-year earnings per share (EPS) guidance of $5.90 to $6.00 falls short of the $6.05 analyst consensus.
This cautious earnings outlook is attributable to various factors. Chief among them are tariff pressures and costs associated with the separation of the MiniMed business. These costs are expected to impact the company’s financial performance and have been factored into the conservative EPS guidance.
Medtronic’s Strategic Actions
Despite the slightly conservative earnings forecast, Medtronic is making strategic moves to secure its future growth. The company is investing in innovation and recently increased its quarterly dividend, signaling confidence in its financial outlook.
Additionally, Medtronic successfully completed the initial public offering (IPO) for its MiniMed business. This move established MiniMed as a separate, publicly traded company, allowing Medtronic to focus on its core operations while providing MiniMed with the autonomy to pursue its own growth strategies.
In conclusion, while the revised stock price target from Stifel Nicolaus might suggest a more modest outlook for Medtronic, the company’s strong financial performance and strategic initiatives are promising. The market will be closely watching how the company navigates tariff pressures, the MiniMed separation costs, and other challenges in the coming period to meet its projected targets.